Subscribe To
Syfovre® (pegcetacoplan injection) continued to demonstrate increasing treatment effects over 3 years in patients with geographic atrophy (ga)
SYFOVRE reduced nonsubfoveal GA lesion growth by over 40% (monthly) in Year 3 compared to projected sham in the GALE extension study Well-demonstrated...
November 4, 2023, 5:37 pm
Candel therapeutics presents preclinical data from its enlighten™ discovery platform at sitc
The first experimental agent from the enLIGHTEN™ Discovery Platform is Alpha-201-macro1, an investigational viral immunotherapy designed to activate...
November 4, 2023, 12:00 pm
Replimune presents updated interim results from the artacus clinical trial of rp1 monotherapy in solid organ and hematopoietic cell transplant recipients with skin cancers during oral presentation at
RP1 as monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent in evaluable ...
November 3, 2023, 11:30 pm
Replimune presents updated interim results from the artacus clinical trial of rp1 monotherapy in solid organ and hematopoietic cell transplant recipients with skin cancers during oral presentation at
RP1 as monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent in evaluable ...
November 3, 2023, 11:30 pm
Replimune presents updated interim results from the artacus clinical trial of rp1 monotherapy in solid organ and hematopoietic cell transplant recipients with skin cancers during oral presentation at
RP1 as monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent in evaluable ...
November 3, 2023, 11:30 pm
Replimune presents updated interim results from the artacus clinical trial of rp1 monotherapy in solid organ and hematopoietic cell transplant recipients with skin cancers during oral presentation at
RP1 as monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent in evaluable ...
November 3, 2023, 11:30 pm
Elicio therapeutics presents updated preliminary immunogenicity data from the ongoing phase 1 study of eli-002 and new preclinical data on eli-007 and eli-008 at the society for immunotherapy of cance
In patients with high relapse risk mKRAS-driven pancreatic and colorectal cancers who were given ELI-00...
November 3, 2023, 8:30 pm
Elicio therapeutics presents updated preliminary immunogenicity data from the ongoing phase 1 study of eli-002 and new preclinical data on eli-007 and eli-008 at the society for immunotherapy of cance
In patients with high relapse risk mKRAS-driven pancreatic and colorectal cancers who were given ELI-00...
November 3, 2023, 8:30 pm
Kineta reports third quarter 2023 financial results and provides corporate update
Announced positive KVA12123 monotherapy safety data from its ongoing phase 1/2 VISTA-101 clinical trial Enrolled the first patient of KVA12123 in comb...
November 3, 2023, 8:01 pm
Actinium pharmaceuticals: the trickle down continues, and i maintain a buy
Actinium Pharmaceuticals continues to make progress with their radiolabelled CD45 antibody Iomab-B, which has potential beyond market expectations. Th...
November 3, 2023, 6:08 pm
Protara therapeutics announces third quarter 2023 financial results and business update
Dosing is progressing well in ADVANCED-1EXP trial evaluating TARA-002 in NMIBC patients with CIS; preli...
November 3, 2023, 12:00 pm
Galectin therapeutics to share five scientific presentations at the liver meeting™ 2023, hosted by the aasld
Pharmacokinetics and safety of belapectin in patients with hepatic insufficiency Lack of impact of bela...
November 3, 2023, 12:00 pm
Morphic announces corporate highlights and financial results for the third quarter 2023
-Presented positive EMERALD-1 Phase 2a data for MORF-057 in patients with moderate to severe ulcerative...
November 3, 2023, 11:00 am
Why is werewolf therapeutics (howl) stock up 20% today?
Werewolf Therapeutics (NASDAQ: HOWL ) stock is on the rise Friday after the company released preliminary data from the phase 1/1b clinical trial. This...
November 3, 2023, 10:26 am
Cidara therapeutics provides corporate update and reports third quarter 2023 financial results
SAN DIEGO, Nov. 02, 2023 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company focused on developing targeted therapi...
November 2, 2023, 8:15 pm
Pantheon vision raises $2.5 million in seed funding to launch development of bioengineered corneal implant
The medical device startup is focused on addressing significant unmet needs of patients suffering from ...
November 2, 2023, 6:06 pm
Genfit to present update on scientific and corporate progress at the liver meeting® 2023
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), November 2 2023 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage bio...
November 2, 2023, 5:10 pm
Assertio holdings, inc. to release third quarter 2023 financial results on november 8, 2023
LAKE FOREST, Ill., Nov. 02, 2023 (GLOBE NEWSWIRE) — Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharma...
November 2, 2023, 4:06 pm
Inari medical to present at upcoming investor conferences
IRVINE, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat a...
November 2, 2023, 4:01 pm
In8bio to present new positive data from phase 1 trial of inb-100 at 2023 american society of hematology (ash) annual meeting
New data on the completed dose-escalation of this Phase 1 trial highlights promising efficacy of INB-100 in pa...
November 2, 2023, 1:17 pm